Companies in the News

7.26.2017

July 26, 2017 at 7:30 PM EDT
WESTLAKE VILLAGE, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the pricing of the Company’s initial public offering of 4,333,333 shares of common stock at a public offering price of $15.00 per share, before underwritin...

7.24.2017

July 24, 2017 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators for the treatment of cancer, today announced that the company has raised $38.6M in Series C financing. Pfizer Venture Investments (PVI) led the round and was joined by additional new investors incl...

6.20.2017

South San Francisco, Calif. – June 20, 2017 – BlackThorn Therapeutics, a clinical-stage biopharmaceutical company discovering and developing targeted treatments for neurobehavioral disorders, today announced it has received a grant from the National Institute of Neurological Disorders and Stroke (NINDS) o...

6.20.2017

SAN DIEGO, June 20, 2017 /PRNewswire/ -- eFFECTOR Therapeutics announced today it has entered into a clinical collaboration and supply agreement with Pfizer and Merck KGaA, Darmstadt, Germany, to evaluate the combination of two immuno-oncology agents in patients with microsatellite stable colorectal cance...

6.7.2017

BLACKTHORN’S BTRX-246040 NOCICEPTIN PROGRAM IS FIRST MOLECULE AND CLINICAL PROGRAM TO INCORPORATE MINDSTRONG HEALTH’S PATENTED TECHNOLOGY PLATFORM

South San Francisco, Calif. – June 7, 2017 – BlackThorn Therapeutics, a clinical-stage biopharmaceutical company discovering and developing targeted treatments...

4.24.2017

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Sienna Biopharmaceuticals, Inc., a privately held, clinical stage medical dermatology and aesthetics company, today announced that it completed a $40 million Series B financing led by existing investors ARCH Venture Partners and Venvest Capital. Additional invest...

1.9.2017

  • Indigo™ Cotton demonstrated an average yield improvement of 11% in the target environment of West Texas

  • Farmers experienced productivity gains in diverse growing conditions without increased use of water or agricultural chemicals

  • Novel R&D platform and economic proposition enable continuous...

1.6.2017

-Former Biogen leader George Scangos will be CEO, with Vicki Sato as Chairman of the Board
-Company to apply immune programming at unprecedented scale
-Financing led by ARCH Venture Partners, Bill & Melinda Gates Foundation, diverse group of investors

SAN FRANCISCO, Jan. 6, 2017 /PRNewswire-USNewswire/ --...

12.6.2016

Acquisition Adds Phase IIb Product, Clinical Candidates and Novel Discovery Platform to Sienna's Growing Pipeline


WESTLAKE VILLAGE, Calif., Dec. 6, 2016 /PRNewswire/ -- Sienna Biopharmaceuticals, Inc., a privately held, clinical-stage medical dermatology and aesthetics company, today announced it has acqu...

10.20.2016

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--BlackThorn Therapeutics, a clinical stage biopharmaceutical company discovering and developing targeted treatments for neurobehavioral disorders, announced that it has closed a $40 million Series A financing. The financing was led by founding investor ARCH Ven...

Please reload